Journal article
Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis
JM Sobell, P Foley, D Toth, U Mrowietz, G Girolomoni, J Goncalves, RM Day, R Chen, G Yosipovitch
Acta Dermato Venereologica | ACTA DERMATO-VENEREOLOGICA | Published : 2016
Abstract
Pruritus and skin discomfort/pain negatively impact health-related quality of life (HRQoL). The effects of apremilast, an oral phosphodiesterase 4 inhibitor, on pruritus, skin discomfort/pain, and patient global assessment of psoriasis disease activity (PgAPDA) were assessed in patients with moderate/severe chronic plaque psoriasis in the phase 3 ESTEEM trials. Significant improvements in pruritus and skin discomfort/pain observed at Week 2 with apremilast versus placebo (both studies, p < 0.0001) were sustained through Week 32. Among apremilast-treated patients, improvements in pruritus visual analog scale (VAS) scores correlated with Dermatology Life Quality Index scores (rs = 0.55 [Week 1..
View full abstractGrants
Funding Acknowledgements
These studies were sponsored by Celgene Corporation.The authors thank Irina Khanskaya, John Marcsisin, Claire Barcellona (clinical), Zuoshun Zhang, (statistics), Monica Bilbault, Dale McElveen (clinical operations), Marlene Kachnowski (data management), Ann Marie Tomasetti, Trisha Zhang (programming), and Kamal Shah (safety) of Celgene Corporation for their contributions to the study and/or the manuscript. The authors received editorial support in the preparation of the manuscript from Kathy Covino, PhD, of Peloton Advantage, funded by Celgene Corporation.